Journal List > J Korean Thyroid Assoc > v.5(2) > 1056508

Sohn, Kim, Jang, Kim, and Chung: Usefulness of Measurement of Serum Iodine Level to Assess the Appropriate Low Iodine Diet Preparation

Abstract

Background and Objectives

Low-iodine diet (LID) is generally recommended prior to radioactive iodine (RAI) therapy to increase RAI uptake. Recently, we suggested spot urine iodine/creatinine (I/Cr) ratio as a good alternative method replacing measurement of 24 hr urine iodine excretion for the evaluation of appropriate LID preparation. In next step, we studied to evaluate the usefulness of serum iodine concentration comparing with urine iodine concentration and urine I/Cr ratio to assess LID preparation status.

Materials and Methods

We prospectively measured serum iodine concentration, spot urine iodine concentration, and urine I/Cr ratio in 419 patients with differentiated thyroid carcinoma undergoing LID. Appropriate LID preparation was defined as urine I/Cr ratio less than 66.2 ug/gCr.

Results

There were significant correlations between serum iodine and the spot urine iodine concentrations or urine I/Cr ratio; the correlation coefficient was 0.51 for urine iodine concentration and 0.62 for I/Cr ratio (p<0.001). Calculated R2 after log-log transformation was 0.45 for I/Cr ratio. The cutoff value of serum iodine concentration was 20.4 ug/L (sensitivity 79.3%, specificity 81.5%) for the evaluation of appropriate LID.

Conclusion

Measurement of serum iodine concentration may be useful as an adjunct parameter for assessing LID preparation, but its sensitivity and specificity were relatively low compared to the urine I/Cr ratio.

Figures and Tables

Fig. 1
The relationship between serum iodine and urine iodine levels. (A) Serum iodine levels were significantly correlated with spot urine iodine levels (r=0.51, p<0.001). (B) Serum iodine levels were significantly correlated w ith spot urine I/Cr ratio (r=0.62, p<0.001).
jkta-5-143-g001
Fig. 2
The relationship between serum iodine level and urine I/Cr ratio after log-log transformation. R2 was calculated by linear regression analysis.
jkta-5-143-g002
Fig. 3
Receiver-operating characteristic (ROC) analysis to determine the cutoff value of serum iodine for suggesting appropriate low-iodine diet. The area under the curve (AUC) values for serum iodine level was 0.871 (95% confidence interval, 0.832-0.911). The cutoff value of serum iodine level was 20.4 ug/L (sensitivity 79.3%, specificity 81.5%, p<0.001).
jkta-5-143-g003

Notes

This study was supported by the Korean Thyroid Association-Hanmi Pharm Co. Research Grant (2010) and the Research Grant Number CB-2011-03-02 of the Korean Foundation for Cancer Research.

References

1. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004. 89(8):3668–3676.
crossref
2. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997. 7(2):265–271.
crossref
3. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med. 1983. 8(3):123–126.
crossref
4. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003. 58(4):428–435.
crossref
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006. 16(2):109–142.
crossref
6. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006. 154(6):787–803.
crossref
7. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009. 115(16):3801–3807.
crossref
8. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008. 35(10):1941–1959.
crossref
9. Rasmussen LB, Ovesen L, Christiansen E. Day-to-day and within-day variation in urinary iodine excretion. Eur J Clin Nutr. 1999. 53(5):401–407.
crossref
10. Knudsen N, Christiansen E, Brandt-Christensen M, Nygaard B, Perrild H. Age- and sex-adjusted iodine/creatinine ratio. A new standard in epidemiological surveys? Evaluation of three different estimates of iodine excretion based on casual urine samples and comparison to 24 h values. Eur J Clin Nutr. 2000. 54(4):361–363.
11. Andersson M, Takkouche B, Egli I, Allen HE, de Benoist B. Current global iodine status and progress over the last decade towards the elimination of iodine deficiency. Bull World Health Organ. 2005. 83(7):518–525.
12. Kim HK, Lee SY, Lee JI, Jang HW, Kim SK, Chung HS, et al. Usefulness of iodine/creatinine ratio from spot-urine samples to evaluate the effectiveness of low-iodine diet preparation for radioiodine therapy. Clin Endocrinol (Oxf). 2010. 73(1):114–118.
13. Macours P, Aubry JC, Hauquier B, Boeynaems JM, Goldman S, Moreno-Reyes R. Determination of urinary iodine by inductively coupled plasma mass spectrometry. J Trace Elem Med Biol. 2008. 22(2):162–165.
crossref
14. Goslings BM. Proceedings: Effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata. J Endocrinol. 1975. 64(3):30P.
15. Uyttersprot N, Pelgrims N, Carrasco N, Gervy C, Maenhaut C, Dumont JE, et al. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I- symporter mRNAs in dog thyroid. Mol Cell Endocrinol. 1997. 131(2):195–203.
crossref
16. Soldin OP. Controversies in urinary iodine determinations. Clin Biochem. 2002. 35(8):575–579.
crossref
17. Thomson CD, Smith TE, Butler KA, Packer MA. An evaluation of urinary measures of iodine and selenium status. J Trace Elem Med Biol. 1996. 10(4):214–222.
crossref
18. Konno N, Yuri K, Miura K, Kumagai M, Murakami S. Clinical evaluation of the iodide/creatinine ratio of casual urine samples as an index of daily iodide excretion in a population study. Endocr J. 1993. 40(1):163–169.
crossref
19. Zimmermann MB. Iodine requirements and the risks and benefits of correcting iodine deficiency in populations. J Trace Elem Med Biol. 2008. 22(2):81–92.
crossref
20. World Health Organization, UNICEF, ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers. 2007. 3rd ed. Geneva: World Health Organization.
21. Caldwell KL, Maxwell CB, Makhmudov A, Pino S, Braverman LE, Jones RL, et al. Use of inductively coupled plasma mass spectrometry to measure urinary iodine in NHANES 2000: comparison with previous method. Clin Chem. 2003. 49(6 Pt 1):1019–1021.
crossref
22. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009. 94(5):1612–1617.
crossref
23. Ishigaki K, Namba H, Takamura N, Saiwai H, Parshin V, Ohashi T, et al. Urinary iodine levels and thyroid diseases in children; comparison between Nagasaki and Chernobyl. Endocr J. 2001. 48(5):591–595.
crossref
TOOLS
Similar articles